Enteral Syringe Market Analysis & Forecast: 2026-2033
The enteral syringe market is anticipated to grow at a CAGR of 4.59% with USD 1.15 Bn in 2026 and is expected to reach USD 1.56 Bn in 2033. Increasing number of critical care (Each year, about 5 million patients are admitted to intensive care units in India) and neonatal intensive care unit admissions is expected to drive growth of the global enteral syringes market. This is owing to inability of patients admitted to critical care and newborns admitted to neonatal intensive care (due to premature birth or other complications) to swallow medicine or take nutrition.
Single use enteral syringes is projected to account for the largest share of product type in 2026, representing approximately 40% of the total volume. The paramount importance of infection control protocols in healthcare institutions and the growing emphasis on patient safety standards worldwide are the factors influencing the market growth. Around 1 in every 10 patients is harmed in health care and more than 3 million deaths occur annually due to unsafe care.
Ensuring patient safety during medical care remains a pressing issue with substantial social and economic costs. It is estimated that up to 13% of healthcare spending across OECD countries are contributed to the treatment of patients who are harmed during care.
The World Health Organization's guidelines on infection prevention as well as control have significantly reinforced the adoption of single-use medical devices, particularly in enteral feeding applications where the risk of cross-contamination can lead to severe healthcare-associated infections.
Major healthcare systems across developed nations have implemented strict policies mandating the utilization of single-use enteral syringes to prevent the transmission of pathogens between patients, especially in intensive care units as well as pediatric wards where vulnerable populations are at heightened risk.
To learn more about this report, Request Free Sample
Based on application, cancer dominates the market, accounting for a significant 35% share in 2026, the substantial global cancer burden and the critical need for nutritional support throughout cancer treatment protocols is one of the factors propelling the segment. In 2026, approximately 2,114,850 new cancer cases and 626,140 cancer deaths are projected to occur in the United States.
According to the World Health Organization, cancer remains one of the leading causes of death worldwide, with approximately 10 million deaths recorded in 2020 alone. The segment is further augmented by the complex nutritional challenges that cancer patients face during their treatment journey.
Chemotherapy, radiation therapy, as well as surgical interventions usually result in major side effects including nausea, vomiting, mucositis, gastrointestinal, etc., complications that significantly impair patients' ability to maintain adequate oral nutrition.
Based on patient group, adults dominates the market, accounting for a significant 55% share in 2026, the substantial demographic representation as well as diverse clinical applications requiring enteral nutrition support is one of the factors fueling the market growth.
The adult population encompasses the largest patient cohort globally, including elderly patients with swallowing disorders, critically ill patients in intensive care units, patients with neurological conditions such as stroke and dementia, and those suffering from chronic diseases like cancer, Crohn's disease, and other gastrointestinal disorders. According to a study published by the World Health Organization, the lifetime risk of stroke has increased by 50% over the past 20 years, with 1 in 4 adults predicted to experience a stroke in their lifetime.
According to the World Health Organization, the global population aged 60 years as well as older is expected to increase majorly in the coming decades, with this matrix being particularly susceptible to conditions requiring enteral feeding support.
The high occurance of dysphagia alone affects approximately 15% of elderly adults, as reported by various healthcare institutions, creating a substantial demand for enteral feeding solutions including specialized syringes for medication administration and nutritional support.
Based on end user, hospitals dominates the market, accounting for a significant 60% share in 2026, their extensive infrastructure, high patient volumes, as well as overall enteral nutrition programs that require substantial quantities of enteral syringes for various medical procedures. The unmet need for surgery has continued to grow, reaching at least 160 million operations per year. Ensuring high-quality surgical care remains a crucial global challenge
Hospitals serve as the primary healthcare delivery points where critically ill patients, post-operative cases, as well as individuals with severe swallowing disorders receive enteral nutrition support through feeding tubes. The dominance of hospitals in this market can be attributed to several key factors that establish them as the largest consumers of enteral syringes globally.
ENFit connector technology is a key component in safety improvement in enteral feeding systems. Made with the Global Enteral Device Supplier Association (GEDSA), ENFit connectors have an exquisite design that prevents accidental connections with IV lines, respiratory devices, or other medical equipment. They are easily recognized by their purple color, feature a male/female design incompatible with other systems, comply with ISO 80369-3 standards, as well as allow faster flow with less priming volume.
The technology has been widely adopted in the market. Cardinal Health, for example, transitioned its entire Monoject enteral syringe line to ENFit, provided extensive training to healthcare facilities, and achieved 95% customer satisfaction for improved safety.
|
Current Event |
Description and its Impact |
|
Mandatory ENFit Connector Adoption |
|
|
Stricter FDA and ISO 80369-3 Compliance Rules |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America account 40% market share in 2026, owing to its robust healthcare infrastructure, advanced medical device manufacturing capabilities, and stringent regulatory frameworks that ensure product quality and safety standards. There is 879 Medical Device Manufacturing in the US businesses as of 2026, an increase of 0.9% from 2025.
The presence of world-class medical facilities, including renowned healthcare systems like Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, etc., which consistently adopt innovative medical devices and maintain high standards for enteral feeding procedures is propelling the market growth. There are 2.7 practising doctors per 1 000 population in the United States (OECD average 3.9); and 12.4 practising nurses (OECD average 9.2).
The United States Food and Drug Administration (FDA) has established comprehensive guidelines for enteral feeding devices, including specific requirements for enteral syringes under 21 CFR Part 820, which has made a conducive environment for manufacturers to develop high-quality products that meet rigorous safety standards.
The Asia Pacific region is poised to be the fastest-growing region through 2026-2033, expanding at a CAGR of approximately 7.5%. Driven by rapidly expanding healthcare infrastructure, increasing prevalence of chronic diseases, as well as growing awareness about enteral nutrition benefits across developing economies are the growth-inducing factors. This growth outlook was strongly reinforced by PENSA 2025, the 25th Annual Congress of the Parenteral and Enteral Nutrition Society of Asia, which brought together more than 500 healthcare professionals from across the region to advance clinical knowledge as well as best practices in nutrition therapy.
China's healthcare modernization initiative, supported by substantial investment by government authorities in medical infrastructure, has led to the establishment of thousands of new hospitals and care facilities, each having standardized enteral feeding equipment.
The demographic transition occurring across Asia Pacific, characterized by aging populations in developed markets including South Korea, Japan, etc., combined with improving healthcare standards in emerging markets like Vietnam and Thailand, creates a unique dual-demand scenario.
The U.S. contributes the highest share in the enteral syringe market in North America owing to its robust healthcare infrastructure, extensive hospital network, and advanced medical device regulatory framework.
The U.S. healthcare system's focus on home healthcare services has majorly driven demand for enteral syringes, particularly as the aging population continues to grow as well as require long-term nutritional support.
According to the U.S. Census Bureau, the population aged 65 and older is projected to reach 95 million by 2060, making major demand for enteral feeding solutions. The prevalence of chronic diseases including dysphagia, neurological disorders, cancer, etc., in the U.S. has necessitated increased utilization of enteral nutrition therapy.
China contributes the highest share in the enteral syringe market in APAC owing to its robust healthcare infrastructure development and substantial government investments in medical device manufacturing capabilities.
Its well-established medical device production ecosystem, which has been significantly enhanced through the "Made in China 2025" initiative is one of the factors propelling the growth of the country.
China's leading position is exemplified by the rapid expansion of enteral nutrition programs across its healthcare facilities, particularly following the COVID-19 pandemic when the importance of nutritional support for critically ill patients became paramount.
The Chinese government authorities implementation of the Healthy China 2030 blueprint has accelerated the adoption of standardized enteral feeding protocols in hospitals nationwide, creating substantial demand for specialized syringes designed for enteral administration.
Some of the major key players in Enteral Syringe market include, B. Braun Melsungen AG, GBUK Enteral Ltd., Thermo Fischer, Inc., Koninklijke Philips N.V., Miktell Ltd., Baxter International, Inc., Cardinal Health, Inc., Terumo Corporation, Kentec Medical, Inc., Vygon S.A.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.15 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.59% | 2033 Value Projection: | USD 1.56 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
B. Braun Melsungen AG, GBUK Enteral Ltd., Thermo Fischer, Inc., Koninklijke Philips N.V., Miktell Ltd., Baxter International, Inc., Cardinal Health, Inc., Terumo Corporation, Kentec Medical, Inc., Vygon S.A. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
